Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of non‑alcoholic fatty liver disease via adenosine monophosphate‑activated protein kinase pathway activation

Sun,Wei‑Ming; Wang,Yu‑Ping; Duan,Yong‑Qiang; Shang,Hong‑Xia; Cheng,Wei‑Dong

doi:10.3892/mmr.2014.2327

Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of non‑alcoholic fatty liver disease via adenosine monophosphate‑activated protein kinase pathway activation

Authors:
- Wei‑Ming Sun
- Yu‑Ping Wang
- Yong‑Qiang Duan
- Hong‑Xia Shang
- Wei‑Dong Cheng
View Affiliations

Affiliations: Institute of Integrated Chinese and Western Medicine, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Basic Courses, Gansu College of Traditional Chinese Medicine, Lanzhou, Gansu 730000, P.R. China
Published online on: June 13, 2014 https://doi.org/10.3892/mmr.2014.2327
Pages: 1237-1244
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxidative stress and excess hepatic lipid accumulation contribute to non‑alcoholic fatty liver disease. Radix Hedysari polysaccharides (RHP) have attracted interest due to their antioxidant properties and immunomodulatory effects. However, the effect of RHP on hepatic lipid metabolism remains to be elucidated. In the present study, the response of Sprague‑Dawley rat livers to a high‑fat diet and RHP treatment was investigated by evaluating body weight, liver histology, hepatic lipid content, adenosine monophosphate‑activated protein kinase (AMPK) activity and lipid metabolism gene transcriptional profiles. The present study demonstrated that RHP ameliorated lipid metabolism disorders, regulated hepatic lipid content, improved liver inflammation and damage, activated AMPK via phosphorylation, upregulated peroxisome proliferator‑activated receptor α and downregulated the mRNA expression of sterol regulatory element binding protein‑1c in rat livers, which reduced lipogenesis and increased lipolysis. Taken together, these results suggested that RHP effectively ameliorates lipid metabolism disorders in rat livers; thus, RHP may be a potential therapeutic agent in the prevention of hepatic steatosis.

View Figures

View References

1	Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43:S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
2	Targher G: Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Med. 24:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
3	Koot BG, van der Baan-Slootweg OH, Tamminga-Smeulders CL, et al: Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Arch dis Child. 96:669–674. 2011. View Article : Google Scholar : PubMed/NCBI
4	Park HJ, DiNatale DA, Chung MY, et al: Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem. 22:393–400. 2011. View Article : Google Scholar : PubMed/NCBI
5	Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol. 85:1330–1340. 2013. View Article : Google Scholar : PubMed/NCBI
6	Wei D, Cheng W, Wei Y and Zhang L: Phosphorylated modification and in vitro antioxidant activity of Radix Hedysari polysaccharide. Glycoconj J. 29:167–172. 2012. View Article : Google Scholar : PubMed/NCBI
7	Hui HP, Feng SL, Hu FD, Cui F and Wu YQ: Study on antioxidative activity of polysaccharide from radix hedysari in vitro. J Anhui Agri Sci. 38:4056–4057. 2010.
8	Liu J, Deng W, Fan L, et al: The role of radix hedysari polysaccharide on the human umbilical vein endothelial cells (HUVECs) induced by high glucose. Eur J Intern Med. 23:287–292. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wei D, Wei Y, Cheng W and Zhang L: Sulfated modification, characterization and antitumor activities of Radix hedysari polysaccharide. Int J Biol Macromol. 51:471–476. 2012. View Article : Google Scholar : PubMed/NCBI
10	Grasselli E, Voci A, Canesi L, et al: Direct effects of iodothyronines on excess fat storage in rat hepatocytes. J Hepatol. 54:1230–1236. 2011. View Article : Google Scholar : PubMed/NCBI
11	Koopman R, Schaart G and Hesselink MK: Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol. 116:63–68. 2001.PubMed/NCBI
12	Bligh EG and Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:911–917. 1959. View Article : Google Scholar : PubMed/NCBI
13	Wang YP, Huang LY, Sun WM, et al: Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma. Cancer Lett. 337:96–106. 2013. View Article : Google Scholar : PubMed/NCBI
14	Huang LY, Wang YP, Wei BF, et al: Deficiency of IRTKS as an adaptor of insulin receptor leads to insulin resistance. Cell Res. 23:1310–1321. 2013. View Article : Google Scholar : PubMed/NCBI
15	Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
16	Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L and Velagic V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 13:4539–4550. 2007.PubMed/NCBI
17	Xiao J, Guo R, Fung ML, Liong EC and Tipoe GL: Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 12:125–135. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sakata R, Nakamura T, Torimura T, Ueno T and Sata M: Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int J Mol Med. 32:989–994. 2013.
19	Vuppalanchi R and Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 49:306–317. 2009. View Article : Google Scholar
20	Musso G, Cassader M and Gambino R: Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol. 22:489–496. 2011. View Article : Google Scholar : PubMed/NCBI
21	Matthew Morris E, Fletcher JA, Thyfault JP and Rector RS: The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol. 378:29–40. 2013.PubMed/NCBI
22	Kato J, Koda M, Kishina M, et al: Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med. 30:107–113. 2012.PubMed/NCBI
23	Leuschner UF, Lindenthal B, Herrmann G, et al: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2:472–479. 2010. View Article : Google Scholar : PubMed/NCBI
24	Malaguarnera M, Gargante MP, Russo C, et al: L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am J Gastroenterol. 105:1338–1345. 2010. View Article : Google Scholar : PubMed/NCBI
25	Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Inv. 116:1776–1783. 2006. View Article : Google Scholar : PubMed/NCBI
26	Gray S and Kim JK: New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab. 22:394–403. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kawaguchi T, Osatomi K, Yamashita H, Kabashima T and Uyeda K: Mechanism for fatty acid ‘sparing’ effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem. 277:3829–3835. 2002.
28	Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
29	Yoshimura Y, Nishii S, Zaima N, Moriyama T and Kawamura Y: Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-A(y) mice. Biochem Biophys Res Commun. 434:486–491. 2013. View Article : Google Scholar
30	Xu X, So JS, Park JG and Lee AH: Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 33:301–311. 2013. View Article : Google Scholar : PubMed/NCBI
31	Lee JH, Moon MH, Jeong JK, et al: Sulforaphane induced adipolysis via hormone sensitive lipase activation, regulated by AMPK signaling pathway. Biochem Biophys Res Commun. 426:492–497. 2012. View Article : Google Scholar : PubMed/NCBI